AAD 2022: Dupilumab Improves Itch, Skin Lesions in Prurigo Nodularis
At 24 weeks, significantly more patients randomly assigned to dupilumab achieved 4-point reduction in WI-NRS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.